title: Muscarinic suppression in stratum radiatum of CA1 shows dependence on presynaptic M1 receptors and is not dependent on effects at GABA(B) receptors.
abstract: Cholinergic modulation of synaptic transmission is vital to memory processes and may be responsible for setting network dynamics in the hippocampus appropriate for encoding of information. found evidence suggesting M1 receptors cause presynaptic inhibition of glutamatergic transmission, while research supports a role of the M2 receptor. We examined muscarinic inhibition of fEPSPs in stratum radiatum of mice lacking m1 subtype receptors (KO) compared to wild type (WT) controls. WT mice exhibit greater suppression of transmission by muscarine as compared to KO in a dose dependent fashion. Oxotremorine shows no significant difference in suppression between WT and KO, while MCN-A-343, an M1 agonist, exhibits a significant difference between KO and WT, with KO showing no suppression. One hundred micromolar SGS-742, a selective GABA(B) antagonist, fails to affect either normal transmission or muscarinic suppression in either WT or KO suggesting that differences in suppression between the groups is not attributable to differences in GABA(B) receptor activation due to muscarinic activation of GABAergic interneurons. These findings support a role for presynaptic m1 mAChRs in modulation of synaptic transmission in CA1, but indicate that other muscarinic receptor subtypes, such as M2, are also involved in suppression of synaptic potentials.
authors.affiliation: Department of Psychology, Center for Memory and Brain, Boston University, Boston, MA 02215, USA.
authors.forename: T
authors.initials: T
authors.lastname: Kremin
authors.forename: D
authors.initials: D
authors.lastname: Gerber
authors.forename: L M
authors.initials: LM
authors.lastname: Giocomo
authors.forename: S Y
authors.initials: SY
authors.lastname: Huang
authors.forename: S
authors.initials: S
authors.lastname: Tonegawa
authors.forename: M E
authors.initials: ME
authors.lastname: Hasselmo
mesh_terms: D008455:(4-(m-Chlorophenylcarbamoyloxy)-2-butynyl)trimethylammonium Chloride / Q000494:pharmacology*; D000818:Animals; D004305:Dose-Response Relationship, Drug; D005071:Evoked Potentials / Q000187:drug effects; D018756:GABA Antagonists / Q000494:pharmacology*; D006624:Hippocampus / Q000187:drug effects*; D066298:In Vitro Techniques; D007395:Interneurons / Q000187:drug effects; D051379:Mice; D018345:Mice, Knockout; D018721:Muscarinic Agonists / Q000494:pharmacology*; D009415:Nerve Net / Q000187:drug effects; D009943:Organophosphorus Compounds / Q000494:pharmacology*; D043643:Receptor, Muscarinic M1 / Q000187:drug effects* / Q000235:genetics; D018080:Receptors, GABA-B / Q000187:drug effects*; D017661:Receptors, Presynaptic / Q000187:drug effects*; D009435:Synaptic Transmission / Q000187:drug effects*
chemical_list: D018756:GABA Antagonists; D018721:Muscarinic Agonists; D009943:Organophosphorus Compounds; D043643:Receptor, Muscarinic M1; D018080:Receptors, GABA-B; D017661:Receptors, Presynaptic; C079148:(3-aminopropyl)(n-butyl)phosphinic acid; D008455:(4-(m-Chlorophenylcarbamoyloxy)-2-butynyl)trimethylammonium Chloride